Navigation Links
ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Date:9/19/2011

CAMBRIDGE, Mass., Sept. 19, 2011 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced today the expansion of their current research collaboration agreement to test additional small-molecule compounds for the ability to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).  The expanded scope of this collaboration is based on encouraging results from early-stage animal studies conducted in the past year under the existing collaboration.

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

"This collaboration is an important example of how our Institute, built by the ALS community -, is dedicated to speeding the development of new therapies and has become the leader in preclinical validation of potential treatments for ALS.  We are encouraged by these early results and look forward to expanding our partnership with Aestus on behalf of patients today," says Steve Perrin, Ph.D., president and CEO of ALS TDI.

The original research collaboration was established between ALS TDI and Aestus in March 2010 to test a compound identified by Aestus's proprietary gene-based drug discovery platform in an animal model of ALS. Results obtained by ALS TDI using their rigorous pre-clinical drug testing process were encouraging and warranted expansion of the collaboration to test compounds with a similar mode of action.  

"We at Aestus are delighted to expand our research collaboration with ALS TDI to identify novel therapeutics for this devastating disease," says Tage Honore, Ph.D. D.Sc., CEO and founder of Aestus.  "The expansion of our research agreement with ALS TDI is based on a truly collaborative approach involving scientists at both institutions. We are particularly gratified that the encouraging results from experiments at ALS TDI have helped to furt
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
2. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
3. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
4. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
5. Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy
6. Genethon and Childrens Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial
7. RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
8. FDA Approves Dendreons Los Angeles Cancer Immunotherapy Manufacturing Facility
9. Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
10. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
11. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Oklahoma City, OK (PRWEB) May 24, 2013 ... handful of casualties. And following its ravage, the mayor of ... room bill for new houses, said a report from cnn.com. ... offered the tornado victims complimentary Molderizer and Safe Shield to ... according to the report published on May 22, 2013, caused ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") ... science-based research and development, sales and marketing of ... announced today that it is awarding exclusive Vestiage ... of Reluma Skin Illuminating Facial Care. Qualified applicants ... sending an email to info(at)vestiageinc(dot)com and putting RELUMA ...
(Date:5/24/2013)... Quincy Bioscience, a leading research ... calcium-binding proteins to support healthy living, is pleased ... of apoaequorin in Food and Chemical ... British Industrial Biological Research Association. , The ... adverse effects, if any, of apoaequorin, in rats ...
(Date:5/23/2013)... 2013 Die Übersetzungen wurden von ... Bei der englischen Version handelt es sich ... der Teilnehmer einer groß angelegten Asthmaumfrage halten ihren Zustand ... [*] -Definition [1] als kontrolliert gelten können ... einer von vier Denkweisen zugeordnet werden können, die alle ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... 17 Schering-Plough,Corporation (NYSE: SGP ) announced ... filed a New Drug Application with the Japanese,Ministry ... approval,for its novel selective relaxant binding agent (SRBA), ... reverse to rapidly,reverse the effects of certain muscle ...
... PXS;,Nasdaq: PXSL) today announced the Korean regulatory agency ... Aridol., "This is the first Asian approval ... Robertson. "Korea is an important base from which,to ... an estimated 2.5 million,asthma sufferers and yet only ...
... 16 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), ... year ended November 30, 2007. All dollar amounts ... At November 30, 2007, our cash and ... at November 30, 2006. The change in,our cash ...
Cached Biology Technology:Schering-Plough Announces Sugammadex New Drug Application Filed in Japan 2Schering-Plough Announces Sugammadex New Drug Application Filed in Japan 3Pharmaxis' Aridol Gains First Asian Approval 2Vasogen Announces 2007 Year-End Results 2Vasogen Announces 2007 Year-End Results 3Vasogen Announces 2007 Year-End Results 4Vasogen Announces 2007 Year-End Results 5Vasogen Announces 2007 Year-End Results 6Vasogen Announces 2007 Year-End Results 7Vasogen Announces 2007 Year-End Results 8Vasogen Announces 2007 Year-End Results 9Vasogen Announces 2007 Year-End Results 10Vasogen Announces 2007 Year-End Results 11
(Date:5/23/2013)... Frontiers in Plant Science , ... gene content and promoter evolution among grasses , ... of stretches of DNA that undergo little change in ... not code for any proteins. Some of these evolutionarily ... to regulate the expression of other genes or the ...
(Date:5/23/2013)... said to be the world,s most popular fruit, can ... research with purple GM varieties. , "Working with ... by the addition of a specific compound, allows us ... said Professor Cathie Martin from the John Innes Centre. ... with better flavour, health and shelf life characteristics because ...
(Date:5/23/2013)... Wash. Pacific Northwest National Laboratory honored more ... commercialization of intellectual property at PNNL,s annual Intellectual ... , The Department of Energy national laboratory named ... for his work developing battery materials that can ... the electrical grid, and reduce the time it ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... designed, produced and patented a new chemical compound for the ... binds 1,000 times more effectively to the target protein in ... stroke victims. The results of biological tests have just been ... people die each year from stroke in the United States. ...
... Calif., Feb. 21, 2012  ChromaDex Corporation (OTCBB: CDXC), ... science-based solutions and ingredients to the dietary supplement, ... marketer of BluScience™ ( http://www.bluscience.com ), ... today the Board has appointed Debra A. Heim ...
... Euroscience Open Forum 2012 (ESOF 2012) was officially launched today ... place in Dublin this year from 11th to 15th July. ... be held in the heart of the Irish capital, in ... interdisciplinary, pan-European meeting, held under the auspices of Euroscience, which ...
Cached Biology News:Promising new compound for treating stroke 2Promising new compound for treating stroke 3ChromaDex® Names Debra Heim as COO 2ChromaDex® Names Debra Heim as COO 3Science Program announced for Euroscience Open Forum 2012 in Dublin 2Science Program announced for Euroscience Open Forum 2012 in Dublin 3Science Program announced for Euroscience Open Forum 2012 in Dublin 4Science Program announced for Euroscience Open Forum 2012 in Dublin 5